Introduction {#Sec1}
============

Several studies have been performed evaluating the significance of a raised troponin in both ischemic heart disease and non-cardiac conditions \[[@CR1]\]. While it has been found that cardiac troponins are valuable in the diagnosis of acute coronary syndromes (ACS), it has also been shown to be elevated in other cardiac (e.g., heart failure, myositis) and non-cardiac conditions (e.g., sepsis, renal failure, pulmonary embolism) \[[@CR2], [@CR3]\].

The prognosis of patients with non-obstructive coronary artery disease (CAD) is unknown, but recent small studies have found that patients with an elevated troponin level and non-obstructive CAD have an increased risk of death at 1-year follow-up, as well as death and recurrence of myocardial infarction at 2.5 years follow-up \[[@CR4]--[@CR6]\], especially non-cardiac causes of death \[[@CR5]\]. This study was performed to further investigate the outcomes of troponin-positive patients with obstructive and non-obstructive CAD.

Methods {#Sec2}
=======

The analysis in this article does not involve any new studies of human or animal subjects performed by any of the authors. All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000 and 2008.

A retrospective cohort analysis that included all patients who had a raised cardiac troponin T (cTnT; AQT90 FLEX \[Radiometer Medical ApS, Brønshøj, Denmark\], using the 99th percentile value of 0.017 ng/ml) presenting to Kettering General Hospital (Northamptonshire, UK) between the period of January 2010 to December 2011 was performed. These patients were divided into two groups; the first group comprised patients who underwent coronary angiograms and the second group comprised patients who were too high risk for coronary angiograms and were medically managed. The patients who had angiograms were stratified anatomically, into non-obstructive epicardial CAD with \<50% stenosis (NO-CAD) and obstructive epicardial CAD with ≥50% stenosis (O-CAD). The NO-CAD patients were sub-grouped by the cause of raised troponin if this could be identified (NO-CAD-I) versus the group where the cause remained unidentified (NO-CAD-U). Also, the O-CAD cohort was analyzed by management strategy: emergent revascularization (\<12 h); revascularization performed urgently as inpatient (mean of 2 days); delayed revascularization as outpatient; and medical management. The 30 days and 1-year major adverse cardiac and cerebrovascular events (MACCE) and the relative risk (RR) of death in the NO-CAD group were analyzed in comparison to O-CAD group. Furthermore, analyses of the NO-CAD subgroups were compared to the O-CAD subgroups. The Modification of Diet in Renal Disease equation (MDRD) equation was used to calculate the glomerular filtration rate for all patients \[[@CR7]\].

Statistical Methods {#Sec3}
-------------------

The data were analyzed with the use of MedCalc version 12.7.2 (MedCalc Software bvba, Ostend, Belgium). The results were expressed as percentage or mean ± standard deviation for categorical and continuous variables, respectively, due to normal population distribution. Significant differences between groups were assessed by *χ*^2^ test and Student's *t* test in comparing between nominal and continuous variables, respectively. One-way analysis of variance test was used instead of Student's *t* test in cases of more than two quantitative variables. Significance was ascribed with probability \<0.05. The Kaplan--Meier survival curve was performed to compare the rate of mortality at 30 days and 1-year follow-up between the groups.

Results {#Sec4}
=======

A total of 1,351 patients who presented to Kettering General Hospital with raised cTnT (from January 2010 to December 2011) were assessed included in the study. Of these, 962 patients (71.2%) had coronary angiography, and 389 patients (28.8%) were too high risk for angiography and were therefore medically managed. These patients had multiple comorbidities, which included severe renal impairment, peripheral vascular disease or critical illness requiring mechanical ventilation. Patients who had coronary angiography were stratified anatomically into those with O-CAD (847 patients, 62.6%) and NO-CAD (115 patients, 8.5%; Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Total number of patients. CAD, coronary artery disease

The NO-CAD-I comprised 80 patients (69.5%) and the NO-CAD-U comprised 35 patients (30.4%). The O-CAD group comprised 374 patients who had emergency revascularization (44.2%), 184 patients who had urgent revascularization as an inpatient (21.7%), 114 patients who were discharged and returned for delayed outpatient revascularization (13.4%), and 175 patients who were managed medically (20.6%).

The mean age was equivalent between both groups and there were more female patients in the NO-CAD group when compared with the O-CAD. Comparing for risk factors for CAD showed that the NO-CAD group had a significant preponderance of hypertension (73 patients, 63% vs. 435 patients, 51%, *P* = 0.0068; Table [1](#Tab1){ref-type="table"}).Table 1Demographics and risk factors for CADDemographics and risk factors for CADNon-obstructive CAD groupObstructive CAD group*P* value*N* = 115 (8.5%)*N* = 847 (62.7%)Age, years ± SD67.3 ± 14.166.4 ± 130.981Gender Male56 (48.7)610 (72)0.541 Female59 (51.3)237 (28)Diabetes mellitus18 (15)175 (20)0.220Hypertension73 (63)435 (51)0.006Smoker68 (59)468 (55)0.250Ex-smoker17 (14)102 (12)0.397Dyslipidemia8 (7)77 (9)0.454Family history for CAD3 (2)25 (3)0.837Values are given as *N* (%) unless otherwise stated*CAD* coronary artery disease, *SD* standard deviation

The NO-CAD group had a trend toward lower level of cTnT elevation (0.5 ± 0.6 vs. 2.4 ± 4.7, *P* = 0.121) and a longer length of hospital stay (9.1 ± 16.4 vs. 5.3 ± 7.9, *P* = 0.253). The evaluation of the renal functions showed that the NO-CAD group had more patients with severe renal impairment with a glomerular filtration rate \<15 ml/min/1.73 m^2^ (5 patients, 4.3% vs. 5 patients, 0.5%, *P* = 0.0014; Table [2](#Tab2){ref-type="table"}).Table 2Baseline anemia and renal impairmentBlood investigationsNon-obstructive CAD groupObstructive CAD group*P* value*N* = 115 (8.5%)*N* = 847 (62.7%)Hemoglobin, g/dl (±SD)12.7 ± 9.813.4 ± 3.40.639Creatinine, µmol/l (±SD)112.4 ± 9494.9 ± 500.332GFR (rate/min/1.73 m^2^) and grade of renal impairment^a^GFR \>6076 (66)640 (75.5)0.054IIIa 45--59.918 (15.6)107 (12.6)0.360IIIb 30--44.98 (6.9)72 (8.5)0.576IV 15--29.98 (6.9)24 (2.8)0.023V \<155 (4.3)5 (0.5)0.0014Values are given as *N* (%) unless otherwise stated^a^ Grades of renal impairment by MDRD equation

The comparison between the echocardiographic findings showed no structural heart disease by echocardiogram in the NO-CAD group (43 patients, 37% vs. 178 patients, 21%, *P* \< 0.0001) and more patients with aortic valve disease and left ventricular hypertrophy (Table [3](#Tab3){ref-type="table"}).Table 3Echocardiographic findingsEchocardiographic findingsNon-obstructive CAD groupObstructive CAD group*P* value*N* = 115 (8.5%)*N* = 847 (62.7%)Normal echocardiogram^a^43 (37.4)178 (21)\<0.0001Severe/Moderate aortic valve disease8 (6.9)13 (1.5)0.0005Moderate to severe LVH10 (8.7)19 (2.2)0.0003Severe LV systolic impairment (EF \<35%)10 (8.7)61 (7.2)0.2615Moderate LV systolic impairment (EF 44--35%)11 (9.5)116 (13.7)0.2306Mild LV systolic impairment (EF 45--55%)11 (9.5)144 (17)0.0525Regional wall motion abnormality16 (13.9)387 (45.7)\<0.0001Hypertrophic cardiomyopathy (Confirmed by CMR)1 (0.8)0 (0.0)0.0582Takotsubo cardiomyopathy1 (0.8)0 (0.0)0.0582Moderate to severe valvular heart disease2 (1.7)35 (4.1)0.2295Others (Right ventricular function impairment, Pulmonary hypertension, ASD, VSD or Previous valve replacement)8 (6.9)50 (5.9)0.6551No echocardiogram16 (13.9)137 (16.1)0.5383Values are given as *N* (%)^a^ Normal echocardiography with no structural heart disease

The 30 days MACCE and mortality rates were similar between the NO-CAD and O-CAD groups \[30 days MACCE: RR (95% CI) = 0.72 (0.29--1.77), *P* = 0.47; 30 days all-cause mortality: RR (95% CI) = 1.24 (0.54--2.86), *P* = 0.6124\]. At 1-year follow-up, the MACCE rate between the NO-CAD and the O-CAD groups was also equivalent \[RR (95% CI) = 1.21 (0.75--1.96), *P* = 0.43\], with similar 1-year mortality in both groups \[RR (95% CI) = 0.93 (0.53--1.64), *P* = 0.803; Table [4](#Tab4){ref-type="table"}\].Table 430 days and 1-year MACCE and mortality follow-upFollow-upNon-obstructive CAD groupObstructive CAD groupRelative risk (95% CI)*P* value*N* = 115 (8.5%)*N* = 847 (62.7%)30 days follow-upMACCE5 (4.3)51 (10.4)0.7221 (0.29--1.77)0.4771Death Total6 (5.2)39 (4.6)1.24 (0.54--2.86)0.6124 Cardiac4 (3.4)30 (3.5)0.98 (0.35--2.74)0.9723 Non-cardiac2 (1.7)9 (1.0)1.63 (0.36--7.48)0.52521-year outcomeMACCE15 (13.0)131 (15.4)0.84 (0.51--1.39)0.5021 Total12 (10.4)95 (11.2)0.93 (0.53--1.64)0.8032 Cardiac5 (4.3)48 (5.6)0.77 (0.31--1.89)0.5640 Non-cardiac7 (6.0)43 (5.0)1.2 (0.55--2.60)0.6461MI STEMI2 (1.7)24 (2.8)0.61 (0.12--2.56)0.5033 NSTE-ACS0 (0.0)25 (2.9)0.14 (0.01--2.34)0.1727Unplanned revascularization2 (1.7)49 (5.8)0.3 (0.07--1.22)0.0925CVA/TIA1 (0.8)7 (0.8)1.05 (0.13--8.47)0.9619Major bleeding^a^3 (2.6)24 (2.8)0.92 (0.28--3.01)0.8912*CAD* coronary artery disease, *CVA* cerebrovascular stroke, *MACCE* major adverse cardiac and cerebrovascular events, *MI* myocardial infarction, *NSTE-ACS* non-ST elevation ACS, *STEMI* ST elevation myocardial infarction, *TIA* transient ischemic attack^a^ Major bleeding that required blood transfusion

The subgroup analysis of the NO-CAD group showed that the 35 patients who had no identifiable cause for the cTnT elevation were a low-risk group (MACCE at 1-year = 0). In the NO-CAD group, the most common identified causes were tachyarrhythmia (21%), respiratory failure/severe pneumonia (6.9%), sepsis (6%), and advanced malignancies (6%; Table [5](#Tab5){ref-type="table"}). When NO-CAD-I group was compared to the O-CAD group, they had similar 30 days MACCE and mortality rates \[30 days MACCE: RR (95% CI) = 1.03 (0.42--2.52), *P* = 0.934; 30 days all-cause mortality: RR (95% CI) = 1.68 (0.71--3.73), *P* = 0.25\]. The 1-year MACCE and mortality follow-up rates were also similar \[1-year MACCE: RR (95% CI) = 1.21 (0.75--1.96), *P* = 0.43; 1-year all-cause mortality: RR (95% CI) = 1.34 (0.77--2.33), *P* = 0.31\].Table 5Causes of raised troponin in non-obstructive CAD groupIdentified cause*N* = 115%Tachyarrhythmia2521.7Respiratory failure/Severe pneumonia86.9Sepsis76.0Advanced malignancy76.0Heart failure65.2Myopericarditis54.34Takotsubo syndrome43.47Aortic valve disease43.47Suspected vasospastic angina21.7Pulmonary embolism21.7Bradyarrhythmia21.7Critically ill with ITU admission21.7Cerebrovascular Stroke00.0Acute kidney injury100.86Aortic dissection10.86Unknown3530.4IHD00.0Post-PCI troponin rise00.0*CAD* coronary artery disease, *ITU* intensive care unit, *PCI* percutaneous coronary intervention

Further comparison of NO-CAD-I patients with the O-CAD subgroups showed no difference in 30 days MACCE and mortality rates. However, at 1-year follow-up, NO-CAD-I patients had higher MACCE rates and overall mortality compared to the emergency re-vascularization group \[1-year MACCE: RR (95% CI) = 2.27 (1.29--3.40), *P* = 0.0047; 1-year all-cause mortality: RR (95% CI) = 2.08 (1.10--3.93), *P* = 0.024\]. This increased mortality was driven by non-cardiac death \[RR (95% CI) = 4.10 (1.53--10.99), *P* = 0.005; Fig. [2](#Fig2){ref-type="fig"}).Fig. 2Kaplan--Meier survival curve. *I/P PCI* inpatient percutaneous coronary intervention, *Medical Mx* medical therapy, *O/P PCI* outpatient percutaneous coronary intervention, *PCI* percutaneous coronary intervention

Discussion {#Sec5}
==========

Previous studies indicated that the detection of the highly specific troponin in blood is an independent risk factor that identifies patients presenting with unstable angina or non-ST elevation myocardial infarction, who are at increased risk of death \[[@CR8], [@CR9]\]. Troponin elevation can be seen in a variety of clinical scenarios, which may lead to its detection in the absence of thrombotic ACSs. Many disease states, such as sepsis, hypovolemia, atrial fibrillation, congestive heart failure, pulmonary embolism, myocarditis, myocardial contusion, renal failure, and critically ill patients can be associated with a raised troponin level (Table [6](#Tab6){ref-type="table"}) \[[@CR9]--[@CR13]\].Table 6Causes of raised troponin• Chronic or acute renal dysfunction• Severe congestive heart failure---acute and chronic• Hypertensive crisis• Tachy- or brady-arrhythmias• Pulmonary embolism, severe pulmonary hypertension• Inflammatory diseases, e.g., myocarditis• Acute neurological disease, including stroke or subarachnoid hemorrhage• Aortic dissection, aortic valve disease or hypertrophic cardiomyopathy• Cardiac contusion, ablation, pacing, cardioversion, or endomyocardial biopsy• Hypothyroidism• Apical ballooning syndrome (Takotsubo cardiomyopathy)• Infiltrative diseases, e.g., amyloidosis, hemochromatosis, sarcoidosis, scleroderma• Drug toxicity, e.g., adriamycin, 5-fluorouracil, Herceptin, snake venoms• Burns, if affecting \>30% of body surface area• Rhabdomyolysis• Critically ill patients, especially with respiratory failure, or sepsisInformation from: European Society of Cardiology (ESC) Guidelines for the management of ACS in patients presenting without persistent ST-segment elevation. The Task Force for the management of ACS in patients presenting without persistent ST-segment elevation of the ESC, 2011 \[[@CR16]\]

In several studies of ACSs, troponin elevation has been associated with a worse prognosis \[[@CR9], [@CR14]\]. However, troponin elevation in the absence of thrombotic ACS still retains the prognostic value \[[@CR9]\]. The risk for subsequent death appears to be related to the degree of troponin elevation \[[@CR8]\]. There is a significant increase in mortality with increasing levels of troponin, and the RR for death is 7.8 in patients with the high troponin levels compared to those with normal levels \[[@CR8]\]. The short- and long-term survival rates are impaired among patients with troponin elevation in many different clinical settings, including congestive heart failure, sepsis, pulmonary disease, acute pulmonary embolism, and renal insufficiency \[[@CR15]\]. The reasons for this increase in mortality are currently poorly understood, but may be related to myocardial necrosis with myocyte loss or underlying quiescent CAD \[[@CR9]\].

These findings challenge the idea that these are "false-positive" troponin elevations and that these patients may be regarded as low risk for subsequent cardiovascular events \[[@CR16]\]. Elevation of troponin in these patients may result from coronary atherothrombosis not evident using standard angiography or from other ischemic and non-ischemic mechanisms \[[@CR16]\]. It was also previously shown that the incidental troponin rise was more common in older patients and was associated with a poorer prognosis compared to ACSs \[[@CR17]\]. Given this substantially increased risk for adverse outcomes, patients with troponin elevation in general require appropriate diagnostic evaluation and therapy aimed at the underlying disorder \[[@CR9]\].

A previous study by Mehta et al. \[[@CR4]\] compared patients who had elevated troponin levels and \<50% stenosis of any major coronary artery on angiography (*n* = 83) to patients with negative troponin levels. The patients with elevated troponin and non-obstructive-epicardial CAD had an increased incidence of death and recurrence of myocardial infarction at 2.5 years follow-up \[[@CR4]\].

The current study compared patients with elevated cTnT with non-obstructive CAD versus obstructive epicardial CAD. The MACCE rate was similar at 30 days and 1-year follow-up. The mortality rate at 30 days follow-up for the non-obstructive CAD was 5.2% vs. 4.6% in the high-risk obstructive CAD group with a RR (95% CI) of 1.24 (0.54--2.86) (*P* = 0.61). The rate of mortality at 1-year follow-up was 10.4% vs. 11.2% with a RR (95% CI) of 0.93 (0.53--1.64) (*P* = 0.8). This was similar to the results of the previous sub-study of the ACUITY trial, which showed that the patients with non-ST elevation ACS and elevated troponin but without obstructive CAD are still at considerable risk for 1-year mortality from cardiac and non-cardiac causes \[[@CR5]\]. This may be caused by unstable, ruptured plaques, but with no significant coronary lesions by angiography.

A small study by Ohlmann et al. \[[@CR18]\] evaluated patients who had intravascular ultrasound showing ruptured plaques with no significant angiographic disease. They had a high death rate of 6% and a major adverse cardiac events (MACE) rate of 18% at a mean follow-up of 43 months \[[@CR18]\].

This was also similar to the TACTICS-TIMI-18 sub-study, which followed a total of 895 patients, from which 32 patients had positive troponin and non-obstructive CAD and they were compared to the three other groups for 6-month mortality, re-infarction, or re-admission for ACS at 6-month follow-up. This sub-study demonstrated that those patients had an adverse prognosis with no significant difference in outcome between troponin-positive patients with CAD compared with those without CAD (*P* = 0.20) \[[@CR16], [@CR19]\]. However, this was in contrary to the previous study by Segev et al. \[[@CR17]\] which showed that the patients with non-obstructive CAD had a benign clinical outcome compared with those with normal coronary arteries during an intermediate term follow-up of 2.5 years with equal low MACE rate between the two groups. (1% for both groups; *P* = 0.9) \[[@CR17]\].

Subgroup analysis has not previously been carried out. By sub-grouping the non-obstructive CAD group, we have shown that patients in the non-obstructive CAD group with no identified cause for the raised troponin were at low risk at 1-year follow-up (MACCE at 1-year = 0). In the non-obstructive CAD group with identified cause, the most common causes of raised troponin were tachyarrhythmia, respiratory failure/severe pneumonia, sepsis and advanced malignancies (Table [6](#Tab6){ref-type="table"}). This has been demonstrated in previous studies, with elevation Troponin in many different clinical settings, including congestive heart failure, sepsis, pulmonary disease, acute pulmonary embolism, and renal insufficiency \[[@CR20]--[@CR22]\]. The mechanism of troponin release is unknown in the absence of flow-limiting CAD, suggesting the presence of mechanisms other than thrombotic coronary artery occlusion, probably a transient loss in membrane integrity with subsequent troponin leakage or micro-vascular thrombotic injury \[[@CR23]\].

Further comparison of this non-obstructive CAD group with identified cause to the obstructive CAD management subgroups demonstrated that these patients had higher 1-year MACCE rate and overall mortality compared with the emergency revascularized group. This increased mortality was driven by higher risk of non-cardiac death \[RR (95% CI) = 4.10 (1.53--10.99), *P* = 0.005; Fig. [2](#Fig2){ref-type="fig"}).

Conclusion {#Sec6}
==========

Patients with a raised troponin and non-obstructive CAD with an identified cause are at equivalent risk of MACCE and death at 30 days and 1-year follow-up compared to those with obstructive CAD. Patients in the non-obstructive CAD group were at a similar risk whether managed with urgent or delayed revascularization or medical therapy for obstructive CAD, with the best outcomes seen in the emergency revascularization group. This finding challenges the prevailing perception that these patients form a low-risk group.
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